Skip to main content
  • Login
  • Contact
  • Subscriptions

Search form

Home

Deer Park Tribune

Deer Park weather

  • Home
  • News
  • Sports
  • Obituaries
  • Entertainment
    • Special Sections
    • Talking About...
  • Photos
  • Videos
  • Classifieds
    • Classified Display Ads
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

463.00 USD +4.40 (+0.96%)
Streaming Delayed Price Updated: 8:40 AM EST, Feb 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,845
Open 458.60
Bid (Size) 463.00 (7)
Ask (Size) 468.00 (5)
Prev. Close 458.60
Today's Range 458.00 - 463.00
52wk Range 418.01 - 664.64
Shares Outstanding 105,949,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Today 7:00 EST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced changes to the Phase 3 trial assessing investigational REGEN-COV™ (casirivimab with imdevimab) in non-hospitalized patients... 
From PR Newswire
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies
February 24, 2021
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert

Performance

YTD
-4.11%
-4.11%
1 Month
-15.54%
-15.54%
3 Month
-8.91%
-8.91%
6 Month
-24.35%
-24.35%
1 Year
+4.67%
+4.67%

More News

Read More
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies
February 24, 2021
From PR Newswire
FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
February 22, 2021
From PR Newswire
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
February 22, 2021
From GlobeNewswire News Releases
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
February 17, 2021
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Thanks to Accelerated COVID-19 Research, New Therapeutic Vaccines May Soon Be Upon Us
February 17, 2021
From PR Newswire
Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies
February 24, 2021
Tags Benzinga News DBTX
From Benzinga
RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today
February 24, 2021
Tags Market News RLFTF LLY
From InvestorPlace
Opthea Outlines OPT-302 Pivotal Study Designs In Chronic Eye Disorder
February 24, 2021
Tags RHHBY Benzinga RHHVF
From Benzinga
Why You Should Keep Your Distance from Ocugen Stock
February 23, 2021
Tags MRNA NASDAQ:OCGN,NYSE:PFE,NYSE:JNJ,NASDAQ:REGN,NYSE:AZN,NASDAQ:MRNA PFE
From InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2020 The Deer Park Tribune | 104 N. Main Street | Deer Park, WA 99006 | (509) 276-5043
All property rights for the entire contents of this publication shall be the property of The Deer Park Tribune.
No part hereof may be reproduced without prior written consent.
Privacy and Terms of Use


Site Design, Programming & Development by Surf New Media